Shin‐ichi Harashima

3.8k total citations · 2 hit papers
69 papers, 2.9k citations indexed

About

Shin‐ichi Harashima is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Shin‐ichi Harashima has authored 69 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Endocrinology, Diabetes and Metabolism, 23 papers in Surgery and 18 papers in Molecular Biology. Recurrent topics in Shin‐ichi Harashima's work include Diabetes Treatment and Management (17 papers), Diabetes Management and Research (15 papers) and Pancreatic function and diabetes (13 papers). Shin‐ichi Harashima is often cited by papers focused on Diabetes Treatment and Management (17 papers), Diabetes Management and Research (15 papers) and Pancreatic function and diabetes (13 papers). Shin‐ichi Harashima collaborates with scholars based in Japan, United States and United Kingdom. Shin‐ichi Harashima's co-authors include Takahiko Horiuchi, Hiroshi Tsukamoto, Hiroki Mitoma, T. Shimoda, Nobuya Inagaki, Jeffrey Unger, Christopher Sorli, Thomas K. Hansen, Stephen C. Bain and Julie Derving Karsbøl and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Immunology and Gastroenterology.

In The Last Decade

Shin‐ichi Harashima

67 papers receiving 2.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Transmembrane TNF- : structure, function and interaction with anti-TNF agents

2010 648 citations Takahiko Horiuchi, Hiroki Mitoma et al. Lara D. Veeken profile →
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

2017 496 citations Shin‐ichi Harashima et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shin‐ichi Harashima Japan	21	944	834	782	457	425	69	2.9k
Yukitaka Ueki Japan	33	640 0.7×	990 1.2×	466 0.6×	1.1k 2.5×	322 0.8×	160	3.5k
Kazuhiro Dohi Japan	31	1.1k 1.1×	866 1.0×	449 0.6×	640 1.4×	317 0.7×	153	3.8k
Rowan Hardy United Kingdom	26	701 0.7×	343 0.4×	633 0.8×	261 0.6×	209 0.5×	58	2.3k
Pier Franco Pignatti Italy	39	1.1k 1.1×	431 0.5×	573 0.7×	390 0.9×	837 2.0×	142	4.4k
Paula M. Oliver United States	22	1.5k 1.6×	918 1.1×	390 0.5×	147 0.3×	328 0.8×	28	3.7k
Ahmed M. Abu El‐Asrar Saudi Arabia	42	1.1k 1.2×	649 0.8×	166 0.2×	644 1.4×	268 0.6×	200	5.4k
Fabienne Burger Switzerland	28	773 0.8×	1.1k 1.3×	338 0.4×	182 0.4×	479 1.1×	54	3.0k
Masahiro Sakata Japan	35	1.1k 1.2×	470 0.6×	160 0.2×	294 0.6×	344 0.8×	162	3.5k
Shue‐Fen Luo Taiwan	37	971 1.0×	906 1.1×	155 0.2×	1.1k 2.4×	476 1.1×	101	3.7k
Raffaele Manna Italy	29	967 1.0×	460 0.6×	183 0.2×	429 0.9×	444 1.0×	161	2.7k

Countries citing papers authored by Shin‐ichi Harashima

Since Specialization

Citations

This map shows the geographic impact of Shin‐ichi Harashima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shin‐ichi Harashima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shin‐ichi Harashima more than expected).

Fields of papers citing papers by Shin‐ichi Harashima

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shin‐ichi Harashima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shin‐ichi Harashima. The network helps show where Shin‐ichi Harashima may publish in the future.

Co-authorship network of co-authors of Shin‐ichi Harashima

This figure shows the co-authorship network connecting the top 25 collaborators of Shin‐ichi Harashima. A scholar is included among the top collaborators of Shin‐ichi Harashima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shin‐ichi Harashima. Shin‐ichi Harashima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Araki, Eiichi, Shin‐ichi Harashima, Tomoyuki Nishida, & Jiro Nakamura. (2022). Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post‐hoc analysis. Journal of Diabetes Investigation. 13(12). 1971–1980. 2 indexed citations

Nishimura, Akiko, Shin‐ichi Harashima, Yu Wang, et al.. (2017). A Large Difference in Dose Timing of Basal Insulin Introduces Risk of Hypoglycemia and Overweight: A Cross-Sectional Study. Diabetes Therapy. 8(2). 385–399. 6 indexed citations

Inagaki, Nobuya, Shin‐ichi Harashima, Nobuko Maruyama, et al.. (2016). Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus. Cardiovascular Diabetology. 15(1). 89–89. 60 indexed citations

Fujita, Yoshihito, Abudukadier Abulizi, Toru Fukushima, et al.. (2015). DEPTOR-related mTOR suppression is involved in metformin's anti-cancer action in human liver cancer cells. Biochemical and Biophysical Research Communications. 460(4). 1047–1052. 27 indexed citations

Nishimura, Akiko, Shin‐ichi Harashima, Yoshiyuki Shimizu, et al.. (2014). Color Record in Self-Monitoring of Blood Glucose Improves Glycemic Control by Better Self-Management. Diabetes Technology & Therapeutics. 16(7). 447–453. 6 indexed citations

Harashima, Shin‐ichi, Akiko Nishimura, Tomoaki Osugi, et al.. (2014). Restless legs syndrome in patients with type 2 diabetes: effectiveness of pramipexole therapy. BMJ Supportive & Palliative Care. 6(1). 89–93. 16 indexed citations

Harashima, Shin‐ichi, Toru Fukushima, Mayumi Sasaki, et al.. (2012). Self‐monitoring of blood glucose (SMBG) improves glycaemic control in oral hypoglycaemic agent (OHA)‐treated type 2 diabetes (SMBG‐OHA study). Diabetes/Metabolism Research and Reviews. 29(1). 77–84. 18 indexed citations

Harashima, Shin‐ichi, Daisuke Tanaka, Shozo Yamane, et al.. (2012). Efficacy and Safety of Switching from Basal Insulin to Sitagliptin in Japanese Type 2 Diabetes Patients. Hormone and Metabolic Research. 45(3). 231–238. 2 indexed citations

Yamane, Shunsuke, Norio Harada, Akihiro Hamasaki, et al.. (2011). Effects of glucose and meal ingestion on incretin secretion in Japanese subjects with normal glucose tolerance. Journal of Diabetes Investigation. 3(1). 80–85. 30 indexed citations

10.

Harashima, Shin‐ichi, Takahiko Horiuchi, Yu Wang, et al.. (2011). Sorting nexin 19 regulates the number of dense core vesicles in pancreatic β‐cells. Journal of Diabetes Investigation. 3(1). 52–61. 17 indexed citations

11.

Yamane, Shunsuke, Yoshiyuki Hamamoto, Shin‐ichi Harashima, et al.. (2010). GLP-1 receptor agonist attenuates endoplasmic reticulum stress-mediated β-cell damage in Akita mice. Journal of Diabetes Investigation. 2(2). 104–110. 15 indexed citations

12.

Horiuchi, Takahiko, Hiroki Mitoma, Shin‐ichi Harashima, Hiroshi Tsukamoto, & T. Shimoda. (2010). Transmembrane TNF- : structure, function and interaction with anti-TNF agents. Lara D. Veeken. 49(7). 1215–1228. 648 indexed citations breakdown →

13.

Harashima, Shin‐ichi, Hiroko Kondo, Kouzaburo Yamaji, et al.. (2008). The relationship between the daily dosage of the carbapenem meropenem (MEPM) and MEPM-resistant Pseudomonas aeruginosa. Journal of Infection and Chemotherapy. 14(3). 219–222. 1 indexed citations

14.

Horiuchi, Takahiko, Chikako Kiyohara, Takuya Sawabe, et al.. (2006). A functional M196R polymorphism of tumour necrosis factor receptor type 2 is associated with systemic lupus erythematosus: a case–control study and a meta-analysis. Annals of the Rheumatic Diseases. 66(3). 320–324. 40 indexed citations

15.

Ikematsu, Hideyuki, et al.. (2006). Safety assessment of coenzyme Q10 (Kaneka Q10) in healthy subjects: A double-blind, randomized, placebo-controlled trial. Regulatory Toxicology and Pharmacology. 44(3). 212–218. 88 indexed citations

16.

Harashima, Shin‐ichi, Takahiko Horiuchi, Nobuaki Hatta, et al.. (2001). Outside-to-Inside Signal Through the Membrane TNF-α Induces E-Selectin (CD62E) Expression on Activated Human CD4+ T Cells. The Journal of Immunology. 166(1). 130–136. 106 indexed citations

17.

Hagiwara, Noriko, et al.. (2001). [A case of Behçet's disease with chronic and repeated sudden hearing loss: successful treatment with intravenous cyclophosphamide pulse therapy].. PubMed. 41(5). 858–63. 4 indexed citations

18.

Morita, Chika, Takahiko Horiuchi, Nobuaki Hatta, et al.. (2001). Association of tumor necrosis factor receptor type II polymorphism 196R with systemic lupus erythematosus in the Japanese: Molecular and functional analysis. Arthritis & Rheumatism. 44(12). 2819–2827. 103 indexed citations

19.

Horiuchi, T., Takuya Sawabe, Shin‐ichi Harashima, et al.. (2000). Behçet's disease associated with complement component 9 (C9) deficiency. Modern Rheumatology. 10(4). 276–278. 1 indexed citations

20.

Horiuchi, Tadao, Hiroaki Nishizaka, Hiroshi Tsukamoto, et al.. (1999). An NcoI polymorphism in the human complement component 7 (C7) gene. Journal of Human Genetics. 44(4). 270–271. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact